|Publication number||US7955613 B2|
|Application number||US 10/574,114|
|Publication date||Jun 7, 2011|
|Filing date||Oct 4, 2004|
|Priority date||Oct 2, 2003|
|Also published as||CA2539150A1, CA2539150C, CN1859934A, CN100536937C, DE602004016008D1, EP1667746A1, EP1667746B1, US20060263405, WO2005030283A1|
|Publication number||10574114, 574114, PCT/2004/1418, PCT/SE/2004/001418, PCT/SE/2004/01418, PCT/SE/4/001418, PCT/SE/4/01418, PCT/SE2004/001418, PCT/SE2004/01418, PCT/SE2004001418, PCT/SE200401418, PCT/SE4/001418, PCT/SE4/01418, PCT/SE4001418, PCT/SE401418, US 7955613 B2, US 7955613B2, US-B2-7955613, US7955613 B2, US7955613B2|
|Inventors||Adam Bruce, Lars Bruce, Bo Nilsson, Olle Korsgren|
|Original Assignee||Tikomed Ab|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (31), Non-Patent Citations (9), Classifications (11), Legal Events (3)|
|External Links: USPTO, USPTO Assignment, Espacenet|
This application claims priority under 35 USC §119 to PCT Application No. PCT/SE2004/001418, filed on Oct. 4, 2004, and Swedish Application No. 0302599-6, filed on Oct. 2, 2003, in the Swedish Patent and Registration Office (PRV), the entire contents of which are incorporated herein by reference.
The technical field of the present invention involves bioartificial implants based on a semipermeable barrier.
It is known in the organ transplantation technique that the human body opposes transplantation of an organ/tissue by rejection phenomena caused by the immune defense of the body. In order to avoid immunosuppressive medicaments (secondary effects, impairment of the immune defense) bioartificial implants have been developed which comprise donor tissue/cells which are to be implanted and a semipermeable barrier or “filter” which is to allow diffusion of nutrients and oxygen from the donee's body to the implanted (i.e. transplanted) donor tissue/cells, but no diffusion of the donee's immune defense mechanisms (cells), while at the same time it shall allow diffusion of desirable substances produced by the donor tissue/cells to the donee's body. Examples in the patent literature concerning such bioartificial implants include U.S. Pat. No. 6,632,244 and WO 02/02745, which discuss particularly implantation of isolated islets of Langerhans (bio-artificial pancreas) for production of insulin in the donee's body. U.S. Pat. No. 6,632,244 also discusses the risk of fibrosis (growth of connective tissue) in the donee's body, which results in the pores of the barrier being covered by connective tissue, whereby the implant “starves to death” (hypoxia), since it does not receive oxygen and nutrients from the donee's body. This phenomenon occurs in barrier materials which are not biocompatible. According to the latter patent, this inconvenience is avoided with a biocompatible implant in the form of a thin sheet of three components (a) a core, which consists of living tissue, trophic factors and nurse cells, an alginate polymer crosslinked with, for instance, calcium, and a fiber net for strength, (b) a coating of alginate polymer crosslinked with calcium for control of permeability, and (c) a coating which also consists of crosslinked alginate polymer. It is recommended that the thickness of the implant not exceed 400 μm.
A transplant which is also coated with alginate (multilayer) is disclosed in U.S. Pat. No. 5,876,742. The coating is said to be non-fibrogenic. The thickness of the coating is 20-200 μm.
U.S. Pat. No. 5,782,912 discloses an implant with a wall consisting of a first porous membrane, which is proximal to the donee's tissue and which is said to favor formation of vascular structures in a donee membrane interface and there prevent formation of connective tissue. The implant also has a second porous membrane, which forms an immuno-isolated space. The space encloses tissue, pancreas islets, which must be protected from being contacted by the donee's cells. The second membrane allows diffusion of components which are generated by the enclosed tissue, producing insulin for instance. The second membrane also allows diffusion of nutrient from the donee to the space in order to provide the tissue with nutrient. The membranes are made of polymer, and the first membrane has a special three-dimensional pore structure. This patent publication states that “Known biocompatible medical implants are composed of ceramics and metals. Assuming these materials could be manipulated to provide the three-dimensional structures described herein, they would also be useful in the present invention”.
U.S. Pat. No. 5,782,912 also discloses use of the device as a coating on an indwelling sensor and on an indwelling catheter, as means for transport of physiological factors to indwelling sensors, as means for transport of drugs from a chamber or catheter to donee tissue and as means for encapsulation of grafted cells for treatment of cellular and molecular deficiencies (immunoisolation).
The above-described implants and other implants based on semipermeable barriers are complicated in design and difficult to produce. There is reason to believe that these circumstances do not result in well-reproducible implants with the desired properties. There is also reason to believe that the vascularising barrier of the known implants is not optimally efficient to prevent fibrosis since a liquid-filled gap between connective tissue and barrier is not taken into consideration.
An object of the invention is to provide such a bio-artificial semipermeable implant of the type described above, i.e. having the property of being vascularising, inhibiting growth of connective tissue (fibrosis), being simpler in design and easier to produce than the known implants.
The object is achieved by an implant having the features in claim 1 and a method according to claim 9. Advantageous embodiments have the features defined in the dependent claims.
The invention is based on our surprising discovery that if a conventional semipermeable barrier, “filter”, “membrane”, adapted to be implanted in the human body and being capable of selectively letting nutrient, oxygen, other gases, tissue/cell substances, cell lines, but no immune defense mechanisms diffuse therethrough, is provided with a permeable coating of biocompatible or bio-active metal, the fibrosis problem will be eliminated significantly.
Experiments performed give us reason to believe that this fibrosis counteracting effect results from the fact that blood vessels in the donee, in which the barrier with the bioactive coating is implanted, are “attracted” to the surface of the coating and grow along the same. As a result, the growth of connective tissue, fibrosis, close to this surface will be blocked, and such growth of connective tissue will not have time to start again before the blood vessels grow close to the surface of the bioactive coating. Blood vessels and growth of blood vessels close to the surface of the bioactive coating result in turn in the fact that nutrient and oxygen from the blood vessels can be transported (diffuse) through the implant unimpeded by connective tissue.
“Attraction” should here not be interpreted as a strictly scientific expression since the mechanism behind the effect has not yet been established. The expression rather means to establish the fact that, according to our findings, blood vessels do not grow (grow insufficiently) to and close to the surface of a conventional barrier—referred to as biocompatible or not—while blood vessels do so close to such a coating on a conventional barrier consisting of bioactive metal.
It should be noted that the metal coating is not to be considered a semipermeable barrier in addition to the conventional semipermeable barrier on which the metal is deposited. This is contrary to the alginate layer or polymer membrane in the patents mentioned above, which adds a vascularising, fibrosis-inhibiting effect to the underlying semipermeable barrier or membrane. The alginate/polymer layer is semipermeable itself and produces permeability of the implant which is a permeability different from that of the underlying semipermeable barrier. The metal coating of an implant according to the invention does not have such an effect.
The semipermeable barrier of the implant, which barrier is made of a polymer material, with the above properties regarding the above-mentioned transports can be of a prior-art type, for instance according to the above-mentioned U.S. Pat. No. 6,372,244, or some other material of a tissue-compatible kind, for instance GoreTex®. Semipermeable barriers of other materials, such as carbohydrates, cellulose, plastic (for example polycarbonate), hydrogels, are already available on the market, marketed by, for instance, Millipore Inc, Baxter Inc, Amicon and Pall Corporation. They are marketed or, on request, produced with different pore sizes depending on what is to be blocked or let through. There are on the market, for instance, semipermeable barriers which block the diffusion of cells (immune defense), but let through molecules (nutrient and oxygen as well as substances from the donee's body in which the barrier is implanted) and substances from the donor's organ/organ part/tissue which is enclosed in the barrier to the donee's body, for instance insulin produced by the islets of Langerhans implanted in the donee's body. The barrier can be in the form of a sheet, in which tissue or cells to be implanted is/are embedded, or in the form of a container (bag, sleeve), in which cells/tissue to be implanted are/is enclosed. In this case, the bioactive coating is at least arranged on the outside of the container.
Bioactive Metal Coating and Deposition Thereof.
The bioactive metal coating of the implant should be permeable, i.e. have pores/openings letting through (diffusion) nutrient, oxygen and tissue/cell substances, i.e. the coating should not interfere with the function and purpose of the semipermeable barrier. However, the pore size need not prevent diffusion of the immune defense; this is taken care of by the semipermeable barrier. The permeability of the coating should thus be at least as great as that of the barrier (while taking into consideration the small effect of the metal coating on the pore walls of the semipermeable barrier). The coating may consist of powder/dust, deposited on the barrier by some prior-art atomizing process, or thin-film technique such as evaporation (PVD), sputtering, or be in the form of a net or a perforated (for instance by laser) foil which is attached in some suitable manner, for instance gluing to the barrier using a biological glue or laser welded thereto. Attaching the foil by sewing is also an acceptable method. “Sprinkling” of grains on the barrier is another option. When choosing a method for depositing the coating on the barrier, the character of the barrier material, especially temperature resistance, should of course be taken into consideration.
The coating should be substantially continuous, by which is meant that connective tissue should be prevented from growing on the underlying semipermeable barrier. While this requirement hardly creates problems if the coating consists of a foil, the requirement must be paid attention to if the coating is deposited on the semipermeable barrier using a method where the coating is composed of particles, deposited, for instance by sputtering, evaporation, chemical precipitation. Thus it must be ensured that the coating of bioactive material on the semipermeable barrier is even and without significant knots that could cause growth of connective tissue. On the other hand, it must also be ensured that the requirement for absence of knots in the coating does not lead to exaggeration in depositing so that the coating becomes excessively thick and, thus, clogs the pores in the semipermeable barrier.
It has been found that excellent results (transport as stated above and preventing of fibrosis) are achieved using today's depositing technique, with a thickness of the metal coating from about 5 nm and more, more preferably about 50-250 nm, independently of the pore size of the barrier.
With reference to that stated above it should be noted that, according to the invention, it cannot be excluded that particles of the bioactive material penetrate when being deposited into the pores/openings of the barrier, thus reducing them, as long as pores/openings remain for said transport or diffusions.
By bioactive metal is meant biocompatible metal which in addition to biocompatibility is capable of—as mentioned above—“attracting” tissue and anchoring this to itself. Such materials are titanium, zirconium, tantalum and suitable alloys thereof, as is already known. According to the invention titanium is preferred.
The difference in terms of connective tissue growth in connection with an implant of a semipermeable barrier without a bioactive metal coating and, according to the invention, with a bioactive metal coating is illustrated in
A titanium coating was deposited on one side of a semipermeable barrier of cellulose, consisting of Diaflo YM5 LOT AN 01383A from Amicon. The deposition occurred by evaporation technique in an evaporator from Edwards Inc. The coating was deposited with a thickness of 30 nm. The result is shown in
The Example was repeated using a filter from Millipore Inc, type SS 3.0 μm. The same results were obtained as in Example 1.
The basic ideas of the invention are applicable not only to semipermeable barriers which enclose donor body tissue/cells to be transplanted in a donee, surviving there by supply of nutrient/oxygen from the donee's body. The inventive idea is also applicable to instruments, measuring elements etc which are to be inserted into the living body to allow transport of substances in general through a semipermeable barrier from opposite sides of the barrier wall. An example of such an application is a blood-sugar-detecting sensor with a semipermeable barrier round the sensor element which is implanted in the human body and connected to an insulin pump for delivering insulin according to the detected blood sugar content via an infusion set inserted in the body and also provided with a semipermeable barrier according to the invention. The inventive problem, i.e. preventing growth of connective tissue close to the barrier, is also in such cases solved by a permeable titanium coating as described above.
Examples of other applications of the invention are drug secretion (chemotherapy, analgesics etc), organ transplantation (kidney, liver etc), cells in bags producing erythropoeitin, coagulation factors, growth hormone, interferon α, parathormones, insulin etc, artificial organs (for instance liver cells), microdialysis technique.
It goes without saying that the invention is applicable to humans as well as animals.
The metal coating may consist of one or more separately deposited metal layers (foil or powder) and the titanium layer/layers can in the implant be in a sandwich construction with the barrier/barriers, if desired for selective transport of substances through the implant.
A TheraCyte™ device, see
The above TheraCyte™device was studied before and after coating with one or two Ti-layers, using a LEICA M76 microscope with an external light source and a Nikon Eclipse E600 light microscope. No change in device-structure due to the Ti-coating procedure could be observed.
Dialysis was performed with the above devices in 0.9% NaCl. Insulin and radioactively labeled glucose, respectively, were introduced in the device. Samples were collected at 0, 15, 30, 60, 120 and 180 minutes after the start of dialysis. Glucose was detected using a liquid scintillation counter, and insulin using IsoInsulin Enzyme ImmunoAssay (EIA). Result: see
TheraCyte™ devices were implanted in male LEWIS rats. After 17 days the devices were removed. On a macroscopic level the non-coated device is surrounded by a capsule containing sera liquid. Cross-sections reveal the existence of a tighter tissue contact for the Ti-coated TheraCyte™ device than the non-coated device. See
This result is fully in agreement with the finding that the titanium coat gives a much tighter bond to the surrounding tissue, thereby allowing glucose to diffuse directly into the tissues and the surrounding blood vessels. By contrast, in the control animal the contact between the bag and the tissue is not tight, which creates a slit between the material and the tissue and a fibrous tissue capsule. Glucose has to diffuse into the fluid of the slit and the fibrous tissue capsule before it reaches the vessels of the tissue. This explains the delay in the increase of the glucose concentration.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US4752294||Feb 26, 1985||Jun 21, 1988||Dan Lundgren||Element for controlled growth into surgically intervened areas|
|US5387327 *||Oct 19, 1992||Feb 7, 1995||Duquesne University Of The Holy Ghost||Implantable non-enzymatic electrochemical glucose sensor|
|US5693514||Sep 2, 1994||Dec 2, 1997||The Regents Of The Univesity Of California||Non-fibrogenic high mannuronate alginate coated transplants, processes for their manufacture, and methods for their use|
|US5782912||Mar 17, 1994||Jul 21, 1998||Baxter International, Inc.||Close vascularization implant material|
|US5800828||Jan 10, 1994||Sep 1, 1998||Brown University Research Foundation||Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products|
|US5843069||Jul 10, 1997||Dec 1, 1998||Gore Hybrid Technologies, Inc.||Implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein|
|US5876742||Nov 26, 1996||Mar 2, 1999||The Regents Of The University Of California||Biological tissue transplant coated with stabilized multilayer alginate coating suitable for transplantation and method of preparation thereof|
|US5913998||Jan 9, 1997||Jun 22, 1999||Gore Hybrid Technologies, Inc.||Method of making an implantable containment apparatus for a therapeutical device|
|US6083523||Sep 4, 1998||Jul 4, 2000||Brown University Research Foundation||Implantable biocompatable immunoisolatory vehicle for delivery of selected therapeutic products|
|US6372244 *||Aug 25, 2000||Apr 16, 2002||Islet Sheet Medical, Inc.||Retrievable bioartificial implants having dimensions allowing rapid diffusion of oxygen and rapid biological response to physiological change, processes for their manufacture, and methods for their use|
|US7527804||Apr 25, 2002||May 5, 2009||Vivoxid Oy||Method for improvement of soft tissue attachment and implants making use of said method|
|US7547471||Jan 31, 2003||Jun 16, 2009||La Jolla Bioengineering Institute||Material for implantation|
|US20030050689 *||Oct 17, 2001||Mar 13, 2003||Surgica Corporation||Surface-modified bioactive suppressant surgical implants|
|US20030108590 *||Jun 18, 2002||Jun 12, 2003||Peery John R.||Osmotic implant with membrane and membrane retention means|
|US20030153981 *||Feb 8, 2002||Aug 14, 2003||Wang Kathy K.||Porous metallic scaffold for tissue ingrowth|
|US20090292191||May 29, 2009||Nov 26, 2009||Bjursten Lars M||Material for implantation|
|EP1476203A1||Jan 31, 2003||Nov 17, 2004||La Jolla Bioengineering Institute||Material for implantation|
|JPH10503964A||Title not available|
|RU2040277C1||Title not available|
|RU2109495C1||Title not available|
|RU2113830C1||Title not available|
|RU2117456C1||Title not available|
|RU2142867C1||Title not available|
|RU2157245C1||Title not available|
|RU2185127C2||Title not available|
|RU2191607C2||Title not available|
|SU209642A||Title not available|
|WO2001070379A1 *||Mar 16, 2001||Sep 27, 2001||Koch Membrane Systems, Inc.||Filtration element for severe service applications|
|WO2001078906A1||Apr 13, 2001||Oct 25, 2001||Virginia Tech Intellectual Properties, Inc.||Self-assembled thin film coating to enhance the biocompatibility of materials|
|WO2002002745A2||Jul 5, 2001||Jan 10, 2002||Islet Technology, Inc.||Method and system for consistent and effective encapsulation of biological material|
|WO2003063925A1||Jan 31, 2003||Aug 7, 2003||La Jolla Bioengineering Institute||Material for implantation|
|1||Belorussian Office Action dated Jan. 13, 2009 in corresponding Application No. 20060401, with English translation.|
|2||Indian Office Action in corresponding Indian Appl. No. 1914/DELNP/2006 dated Sep. 16, 2008.|
|3||International Search Report (PCT/ISA/210), Jan. 3, 2005.|
|4||Japanese Office Action dated Nov. 5, 2010 with English translation for corresponding Japanese Patent Application No. 2006-532233.|
|5||*||LaVan et al., Small-scale systems for in vivo drug delivery, Nature Biotechnology, 2003, vol. 21, p. 1184-1191.|
|6||Melikyan et al., Technical Physics Letters, vol. 28, No. 8, pp. 673-674 (2002).|
|7||*||Okazaki et al., New Ti Alloy without Al and V for Medical implants, Advanced Engineering Materials, vol. 2, No. 5, 2000 p. 278-281.|
|8||Piskin, The International Journal of Artificial Organs, vol. 25, No. 5, pp. 434-440 (2002).|
|9||Shinji Sakai, et al., "Evaluation of Performance of Aminosilica-Titania Membrane As Cell-Encapsulated Immunoisolative Membrane," Proceedings of the Meeting of the Society for Biotechnology, Japan (2001), Aug. 24, 2001, p. 201.|
|U.S. Classification||424/423, 604/890.1, 424/195.17, 623/23.72|
|International Classification||A61F2/00, A61L27/50, A61L27/30|
|Cooperative Classification||A61L27/50, A61L27/306|
|European Classification||A61L27/50, A61L27/30R|
|Mar 31, 2006||AS||Assignment|
Owner name: TIKOMED AB, SWEDEN
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BRUCE, ADAM;BRUCE, LARS;NILSSON, BO;AND OTHERS;REEL/FRAME:017748/0409;SIGNING DATES FROM 20060314 TO 20060316
Owner name: TIKOMED AB, SWEDEN
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BRUCE, ADAM;BRUCE, LARS;NILSSON, BO;AND OTHERS;SIGNING DATES FROM 20060314 TO 20060316;REEL/FRAME:017748/0409
|Jul 10, 2012||CC||Certificate of correction|
|Nov 7, 2014||FPAY||Fee payment|
Year of fee payment: 4